JP2017531033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531033A5 JP2017531033A5 JP2017533726A JP2017533726A JP2017531033A5 JP 2017531033 A5 JP2017531033 A5 JP 2017531033A5 JP 2017533726 A JP2017533726 A JP 2017533726A JP 2017533726 A JP2017533726 A JP 2017533726A JP 2017531033 A5 JP2017531033 A5 JP 2017531033A5
- Authority
- JP
- Japan
- Prior art keywords
- quinidine
- item
- dextromethorphan
- salt
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 128
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 68
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 64
- 229960001404 quinidine Drugs 0.000 claims description 64
- 229960001985 dextromethorphan Drugs 0.000 claims description 35
- 206010012289 Dementia Diseases 0.000 claims description 10
- 238000013019 agitation Methods 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 230000016571 aggressive behavior Effects 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 38
- 239000002552 dosage form Substances 0.000 description 32
- 150000003839 salts Chemical class 0.000 description 29
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 28
- 229960004482 quinidine sulfate Drugs 0.000 description 28
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical class CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 24
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 12
- -1 alkali metal salt Chemical class 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 7
- 206010001497 Agitation Diseases 0.000 description 4
- 239000004381 Choline salt Substances 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 4
- 235000019417 choline salt Nutrition 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 239000012458 free base Chemical class 0.000 description 4
- 229910003002 lithium salt Inorganic materials 0.000 description 4
- 159000000002 lithium salts Chemical class 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 4
- 150000003248 quinolines Chemical class 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
Applications Claiming Priority (35)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050170P | 2014-09-14 | 2014-09-14 | |
| US62/050,170 | 2014-09-14 | ||
| US201462061451P | 2014-10-08 | 2014-10-08 | |
| US62/061,451 | 2014-10-08 | ||
| US201462063122P | 2014-10-13 | 2014-10-13 | |
| US62/063,122 | 2014-10-13 | ||
| US201462063861P | 2014-10-14 | 2014-10-14 | |
| US62/063,861 | 2014-10-14 | ||
| US201462068742P | 2014-10-26 | 2014-10-26 | |
| US62/068,742 | 2014-10-26 | ||
| US201562111053P | 2015-02-02 | 2015-02-02 | |
| US62/111,053 | 2015-02-02 | ||
| US201562111590P | 2015-02-03 | 2015-02-03 | |
| US62/111,590 | 2015-02-03 | ||
| US201562128446P | 2015-03-04 | 2015-03-04 | |
| US62/128,446 | 2015-03-04 | ||
| US201562162140P | 2015-05-15 | 2015-05-15 | |
| US62/162,140 | 2015-05-15 | ||
| US201562165535P | 2015-05-22 | 2015-05-22 | |
| US62/165,535 | 2015-05-22 | ||
| US201562169997P | 2015-06-02 | 2015-06-02 | |
| US62/169,997 | 2015-06-02 | ||
| US201562180026P | 2015-06-15 | 2015-06-15 | |
| US62/180,026 | 2015-06-15 | ||
| US201562193347P | 2015-07-16 | 2015-07-16 | |
| US62/193,347 | 2015-07-16 | ||
| US201562205061P | 2015-08-14 | 2015-08-14 | |
| US62/205,061 | 2015-08-14 | ||
| US201562216636P | 2015-09-10 | 2015-09-10 | |
| US62/216,636 | 2015-09-10 | ||
| US201562217142P | 2015-09-11 | 2015-09-11 | |
| US201562217470P | 2015-09-11 | 2015-09-11 | |
| US62/217,142 | 2015-09-11 | ||
| US62/217,470 | 2015-09-11 | ||
| PCT/US2015/049934 WO2016040930A1 (en) | 2014-09-14 | 2015-09-14 | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019201410A Division JP2020019818A (ja) | 2014-09-14 | 2019-11-06 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017531033A JP2017531033A (ja) | 2017-10-19 |
| JP2017531033A5 true JP2017531033A5 (enExample) | 2017-11-30 |
Family
ID=55459653
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533726A Pending JP2017531033A (ja) | 2014-09-14 | 2015-09-14 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2019201410A Withdrawn JP2020019818A (ja) | 2014-09-14 | 2019-11-06 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2021036318A Active JP7360409B2 (ja) | 2014-09-14 | 2021-03-08 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2023096152A Pending JP2023105265A (ja) | 2014-09-14 | 2023-06-12 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019201410A Withdrawn JP2020019818A (ja) | 2014-09-14 | 2019-11-06 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2021036318A Active JP7360409B2 (ja) | 2014-09-14 | 2021-03-08 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2023096152A Pending JP2023105265A (ja) | 2014-09-14 | 2023-06-12 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190111047A1 (enExample) |
| EP (4) | EP4166141A1 (enExample) |
| JP (4) | JP2017531033A (enExample) |
| KR (1) | KR20170052684A (enExample) |
| CN (3) | CN107072990A (enExample) |
| AU (3) | AU2015314710A1 (enExample) |
| CA (1) | CA2960031A1 (enExample) |
| IL (2) | IL250786A0 (enExample) |
| MX (3) | MX2017003066A (enExample) |
| MY (1) | MY198587A (enExample) |
| PH (1) | PH12017500444A1 (enExample) |
| RU (1) | RU2017112747A (enExample) |
| SG (2) | SG11201701645WA (enExample) |
| TW (3) | TW202106301A (enExample) |
| WO (1) | WO2016040930A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX385316B (es) | 2007-05-01 | 2025-03-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| WO2017020002A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| CA2994153A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| CN115215801A (zh) | 2016-07-04 | 2022-10-21 | 雅芳制药公司 | 氘代右美沙芬的合成方法 |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| MA49464A (fr) * | 2017-05-04 | 2020-04-29 | Exciva GmbH | Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants |
| WO2019222754A1 (en) | 2018-05-18 | 2019-11-21 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| SG11202106392RA (en) * | 2019-01-07 | 2021-07-29 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| EP3941469A4 (en) * | 2019-03-18 | 2022-05-18 | Avanir Pharmaceuticals, Inc. | METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTTERATED DEXTROMETHORPHANE AND QUINIDINE |
| IL296977A (en) * | 2020-04-27 | 2022-12-01 | Avanir Pharmaceuticals Inc | Methods of treating agitation associated with alzheimer's disease |
| CN115245515A (zh) * | 2021-04-27 | 2022-10-28 | 杭州剂泰医药科技有限责任公司 | 一种组合物的医药用途 |
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| CN113209042A (zh) * | 2021-05-28 | 2021-08-06 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法 |
| JP2024540104A (ja) * | 2021-10-27 | 2024-10-31 | アバニア ファーマシューティカルズ， インコーポレイテッド | アルツハイマー病に関連する激越を治療する方法 |
| CN116459255A (zh) * | 2022-01-19 | 2023-07-21 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途 |
| US11730706B1 (en) * | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| CN117783322A (zh) * | 2022-12-16 | 2024-03-29 | 杭州剂泰医药科技有限责任公司 | 右美沙芬奎尼丁组合物的hplc分析方法 |
| KR20250120917A (ko) | 2024-02-02 | 2025-08-11 | 단국대학교 천안캠퍼스 산학협력단 | 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물 |
| KR20250129211A (ko) | 2024-02-22 | 2025-08-29 | 단국대학교 천안캠퍼스 산학협력단 | 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| TW264473B (enExample) * | 1993-01-06 | 1995-12-01 | Hoffmann La Roche | |
| JP4097285B2 (ja) * | 1994-09-22 | 2008-06-11 | リチャード・アラン・スミス | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| ES2352739T3 (es) | 1997-11-21 | 2011-02-22 | Purdue Neuroscience Company | 2-aminoacetamidas sustituidas y el uso de las mismas. |
| EP1069111A4 (en) | 1998-03-26 | 2001-06-06 | Shionogi & Co | INDOLE DERIVATIVES EXER ANT ANTIVIRAL ACTIVITY |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| JP2009525343A (ja) * | 2006-02-03 | 2009-07-09 | アバニール・ファーマシューティカルズ | 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物 |
| WO2007103474A2 (en) * | 2006-03-07 | 2007-09-13 | University Of Florida Research Foundation, Inc. | Drug adherence monitoring system |
| WO2008097924A2 (en) * | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
| MX385316B (es) * | 2007-05-01 | 2025-03-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| AU2008247818B2 (en) * | 2007-05-01 | 2011-10-20 | Sun Pharmaceutical Industries, Inc. | Morphinan compounds |
| MX361542B (es) * | 2008-09-19 | 2018-12-10 | Concert Pharmaceuticals Inc | Compuestos de morfinan. |
| US20120083487A1 (en) * | 2008-10-30 | 2012-04-05 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury |
| ES2444433T3 (es) * | 2008-11-14 | 2014-02-25 | Concert Pharmaceuticals, Inc. | Derivados de dioxopiperidinil-ftalimida sustituidos |
| KR102603013B1 (ko) * | 2013-11-05 | 2023-11-15 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법 |
-
2015
- 2015-09-14 EP EP22195837.4A patent/EP4166141A1/en not_active Withdrawn
- 2015-09-14 SG SG11201701645WA patent/SG11201701645WA/en unknown
- 2015-09-14 JP JP2017533726A patent/JP2017531033A/ja active Pending
- 2015-09-14 CA CA2960031A patent/CA2960031A1/en active Pending
- 2015-09-14 TW TW109114123A patent/TW202106301A/zh unknown
- 2015-09-14 CN CN201580049454.0A patent/CN107072990A/zh active Pending
- 2015-09-14 MY MYPI2017000321A patent/MY198587A/en unknown
- 2015-09-14 MX MX2017003066A patent/MX2017003066A/es unknown
- 2015-09-14 AU AU2015314710A patent/AU2015314710A1/en not_active Abandoned
- 2015-09-14 TW TW110139834A patent/TWI869633B/zh active
- 2015-09-14 CN CN202311175974.9A patent/CN117427077A/zh active Pending
- 2015-09-14 EP EP21178170.3A patent/EP3932907A3/en not_active Withdrawn
- 2015-09-14 TW TW104130311A patent/TW201613591A/zh unknown
- 2015-09-14 SG SG10201901242PA patent/SG10201901242PA/en unknown
- 2015-09-14 US US15/510,498 patent/US20190111047A1/en not_active Abandoned
- 2015-09-14 WO PCT/US2015/049934 patent/WO2016040930A1/en not_active Ceased
- 2015-09-14 KR KR1020177009991A patent/KR20170052684A/ko not_active Ceased
- 2015-09-14 CN CN201910903770.XA patent/CN110664801A/zh active Pending
- 2015-09-14 EP EP20159783.8A patent/EP3708168A3/en not_active Withdrawn
- 2015-09-14 EP EP15840718.9A patent/EP3193872A4/en not_active Withdrawn
- 2015-09-14 RU RU2017112747A patent/RU2017112747A/ru not_active Application Discontinuation
-
2017
- 2017-02-26 IL IL250786A patent/IL250786A0/en unknown
- 2017-03-08 MX MX2021010696A patent/MX2021010696A/es unknown
- 2017-03-08 MX MX2022008181A patent/MX2022008181A/es unknown
- 2017-03-09 PH PH12017500444A patent/PH12017500444A1/en unknown
-
2019
- 2019-10-08 US US16/596,236 patent/US20200289499A1/en not_active Abandoned
- 2019-11-06 JP JP2019201410A patent/JP2020019818A/ja not_active Withdrawn
-
2020
- 2020-05-18 IL IL274742A patent/IL274742A/en unknown
- 2020-12-15 AU AU2020289733A patent/AU2020289733A1/en not_active Abandoned
-
2021
- 2021-03-08 JP JP2021036318A patent/JP7360409B2/ja active Active
-
2022
- 2022-12-06 AU AU2022283671A patent/AU2022283671B2/en not_active Expired - Fee Related
-
2023
- 2023-04-24 US US18/305,589 patent/US20240082237A1/en not_active Abandoned
- 2023-06-12 JP JP2023096152A patent/JP2023105265A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| J Geldenhuys et al. | Rationally designed multi-targeted agents against neurodegenerative diseases | |
| CA2883751C (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| JP2015517488A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2014114295A5 (enExample) | ||
| JP2009525343A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| JP2012193216A5 (enExample) | ||
| JP2015528471A5 (enExample) | ||
| JP2015038135A5 (enExample) | ||
| JP2018529742A5 (enExample) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2016539156A5 (enExample) | ||
| MX2023001014A (es) | Composiciones farmaceuticas que comprenden venglustat. | |
| JP2018530578A5 (enExample) | ||
| JP2012523437A5 (enExample) | ||
| JP2018527305A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| JP2016515137A5 (enExample) | ||
| JP2014530204A5 (enExample) | ||
| RU2015146324A (ru) | Фармацевтические композиции модифицированного высвобождения дексметилфенидата или его солей |